Coronary disease & ACSTrial design
Rationale and design of the vericiguat in vasospastic angina (ViVA) trial: A double-blind placebo-controlled randomized cross-over study
- double-blind placebo-controlled randomized cross-over study
- randomized in a 1:1 ratio
Study context
- Population
- Patients with coronary vasospasm as the pathophysiological substrate of angina and no obstructive coronary arteries (ANOCA)planned enrolment
- Participants
- 50 patients
- Planned comparison
- vericiguat vs placebo
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Rationale and design of the vericiguat in vasospastic angina (ViVA) trial: A double-blind placebo-controlled randomized cross-over study. Am Heart J. Published 23 April 2026. doi:10.1016/j.ahj.2026.107451
Summarised from the published abstract; every number is checked against it